{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T10:19:37Z","timestamp":1780481977590,"version":"3.54.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1007\/s11883-010-0152-1","type":"journal-article","created":{"date-parts":[[2010,12,22]],"date-time":"2010-12-22T05:07:06Z","timestamp":1292994426000},"page":"51-56","source":"Crossref","is-referenced-by-count":46,"title":["Approach to Dyslipidemia, Lipodystrophy, and Cardiovascular Risk in Patients with HIV Infection"],"prefix":"10.1007","volume":"13","author":[{"given":"J. Gregory","family":"Troll","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,12,23]]},"reference":[{"key":"152_CR1","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1055\/s-0038-1656027","volume":"77","author":"M Seigneur","year":"1997","unstructured":"Seigneur, M, Constans, J, Blann, A, et al. Soluble adhesion molecules and endothelial cell damage in HIV infected patients. Thromb Haemost 1997; 77:646.","journal-title":"Thromb Haemost"},{"key":"152_CR2","doi-asserted-by":"crossref","unstructured":"Yu-Min P. Shen, MD, Eugene P. Frenkel, MD Thrombosis and a Hypercoagulable State in HIV-Infected Patients; doi: 10.1177\/107602960401000311 CLIN APPL THROMB HEMOST July 2004 vol. 10 no. 3 277-280","DOI":"10.1177\/107602960401000311"},{"key":"152_CR3","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1055\/s-0037-1615171","volume":"80","author":"M Karmochkine","year":"1998","unstructured":"Karmochkine, M, Ankri, A, Calvez, V, et al. Plasma hypercoagulability is correlated to plasma HIV load. Thromb Haemost 1998; 80:208","journal-title":"Thromb Haemost"},{"key":"152_CR4","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1097\/QAD.0b013e32832d3b85","volume":"23","author":"C Grunfeld","year":"2009","unstructured":"\u2022 Grunfeld, C, Delaney, JA, Wanke, C, et al. Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study. AIDS 2009; 23:1841. This article provides evidence for the effect of HIV infection, rather than HAART, as a causative agent in atherogenesis.","journal-title":"AIDS"},{"key":"152_CR5","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1097\/QAD.0b013e328300581d","volume":"22","author":"RC Kaplan","year":"2008","unstructured":"\u2022 Kaplan, RC, Kingsley, LA, Gange, SJ, et al. Low CD4+ T-cell count as a major atherosclerosis risk factor in HIV-infected women and men. AIDS 2008; 22:1615. This article provides more evidence of the importance of HIV infection as part of the process of atherogenesis. The correlation with CD4+ T cell count suggests either viremia (though not measured directly) or perhaps immunodeficiency as a factor. Immunodeficiency could act as an atherogenic agent either due to inflammatory process or unidentified, uncontrolled vasculopathic infection.","journal-title":"AIDS"},{"key":"152_CR6","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/QAI.0b013e3181a9992c","volume":"51","author":"VA Triant","year":"2009","unstructured":"Triant, VA, Meigs, JB, Grinspoon, SK. Association of C-Reactive Protein and HIV Infection With Acute Myocardial Infarction. J Acquir Immune Defic Syndr 2009; 51:268.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"152_CR7","doi-asserted-by":"crossref","unstructured":"F. De Lorenzo, S. Collot-Teixeira, et al. Metabolic-Inflammatory Changes, and Accelerated Atherosclerosis in HIV Patients: Rationale for Preventative Measures Current Medicinal Chemistry, 2008, 15, 2991-2999 2991 0929-8673\/08 \u00a9 2008 Bentham Scie nce Publishers Ltd.","DOI":"10.2174\/092986708786848668"},{"key":"152_CR8","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/QAD.0b013e328325a87c","volume":"23","author":"D Francisci","year":"2009","unstructured":"Francisci, D, Giannini, S, Baldelli, F, et al. HIV type 1 infection, and not short-term HAART,induces endothelial dysfunction. AIDS 2009; 23:589","journal-title":"AIDS"},{"key":"152_CR9","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Grinspoon, SK, Grunfeld, C, Kotler, DP, et al. State of the science conference: Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV\/AIDS:executive summary. Circulation 2008; 118:198). This is an excellent discussion of relevant articles reviewing the state of the science on this subject.","DOI":"10.1161\/CIRCULATIONAHA.107.189622"},{"key":"152_CR10","unstructured":"Mondy, K.; Overton, E.T.; Grubb, J, et al. Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient population. Clinical Infections Dis., 2007, 44, 726-34."},{"issue":"3","key":"152_CR11","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1089\/met.2009.0094","volume":"8","author":"CR Pullinger","year":"2010","unstructured":"Pullinger CR, Aouizerat BE, Gay C, et al. Metabolic abnormalities and coronary heart disease risk in human immunodeficiency virus-infected adults. Metab Syndr Relat Disord. 2010 Jun; 8(3):279-86.","journal-title":"Metab Syndr Relat Disord."},{"key":"152_CR12","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1097\/00002030-200212060-00010","volume":"16","author":"V Joly","year":"2002","unstructured":"Joly, V, Flandre, P, Meiffredy, V, et al. Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial. AIDS 2002; 16:2447","journal-title":"AIDS"},{"key":"152_CR13","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1097\/01.aids.0000247574.33998.03","volume":"20","author":"GJ Moyle","year":"2006","unstructured":"Moyle, GJ, Sabin, CA, Cartledge, J, et al. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS 2006; 20:2043.","journal-title":"AIDS"},{"key":"152_CR14","doi-asserted-by":"crossref","unstructured":"El Hadri K, Glorian M, Monsempes C, Dieudonn\u00e9 MN, et al. In vitro suppression of the lipogenic pathway by the nonnucleoside reverse transcriptase inhibitor efavirenz in 3\u00a0T3 and human preadipocytes or adipocytes. Chem. 2004 Apr 9;279(15):15130-41. Epub 2004 Jan 13.","DOI":"10.1074\/jbc.M312875200"},{"key":"152_CR15","doi-asserted-by":"crossref","unstructured":"Biol Res Nurs. 2007 Jan;8(3):177-85. Effects of high-intensity endurance and resistance exercise on HIV metabolic abnormalities: a pilot study. Robinson FP, Quinn LT, Rimmer JH.","DOI":"10.1177\/1099800406295520"},{"key":"152_CR16","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1097\/00002030-200404300-00011","volume":"18","author":"A Martin","year":"2004","unstructured":"Martin, A, Smith, DE, Carr, A, et al. Reversibility of lipoatrophy in HIV-infected patients 2\u00a0years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS 2004;18:1029.","journal-title":"AIDS"},{"key":"152_CR17","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1086\/380790","volume":"38","author":"GA McComsey","year":"2004","unstructured":"McComsey, GA, Ward, DJ, Hessenthaler, SM, et al. Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. Clin Infect Dis 2004; 38:263","journal-title":"Clin Infect Dis"},{"key":"152_CR18","doi-asserted-by":"crossref","unstructured":"Amet T, Nonaka M, Dewan MZ, et al. Statin-induced inhibition of HIV-1 release from latently infected U1 cells reveals a critical role for protein prenylation in HIV-1 replication. Microbes Infect. 2008 Apr;10(5):471-80. Epub 2008 Jan 20.","DOI":"10.1016\/j.micinf.2008.01.009"},{"key":"152_CR19","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1086\/378131","volume":"37","author":"MP Dube","year":"2003","unstructured":"Dube, MP, Stein, JH, Aberg, JA, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 2003; 37:613.","journal-title":"Clin Infect Dis"},{"key":"152_CR20","doi-asserted-by":"crossref","first-page":"23K","DOI":"10.1016\/S0002-9149(03)00779-3","volume":"92","author":"HB Brewer Jr","year":"2003","unstructured":"Brewer, HB Jr. Benefit-risk assessment of Rosuvastatin 10 to 40 milligrams. Am J Cardiol 2003; 92:23K","journal-title":"Am J Cardiol"},{"key":"152_CR21","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/QAI.0b013e31815bace2","volume":"47","author":"JG Gerber","year":"2008","unstructured":"Gerber, JG, Kitch, DW, Fichtenbaum, CJ, et al. Fish Oil and Fenofibrate for the Treatment of Hypertriglyceridemia in HIV-Infected Subjects on Antiretroviral Therapy: Results of ACTG A5186. J Acquir Immune Defic Syndr 2008; 47:459","journal-title":"J Acquir Immune Defic Syndr"},{"key":"152_CR22","first-page":"1105","volume":"47","author":"DA Wohl","year":"2008","unstructured":"Wohl, DA, Waters, D, Simpson, RJ Jr, et al. Ezetimibe alone reduces low-density lipoprotein cholesterol in HIV-infected patients receiving combination antiretroviral therapy. Clin Infect Dis 2008; 47:1105.","journal-title":"Ezetimibe alone reduces low-density lipoprotein cholesterol in HIV-infected patients receiving combination antiretroviral therapy. Clin Infect Dis"},{"key":"152_CR23","doi-asserted-by":"crossref","unstructured":"Macallan DC, Baldwin C, Mandalia S, et al. Treatment of altered body composition in HIV-associated lipodystrophy: comparison of rosiglitazone, pravastatin, and recombinant human growth hormone. HIV Clin Trials. 2008 Jul-Aug; 9(4):254-68.","DOI":"10.1310\/hct0904-254"},{"key":"152_CR24","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","volume":"356","author":"SE Nissen","year":"2007","unstructured":"Nissen, SE, Wolski, K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356:2457.","journal-title":"N Engl J Med"},{"key":"152_CR25","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1086\/518008","volume":"195","author":"S Grinspoon","year":"2007","unstructured":"Grinspoon, S. Use of Thiazolidinediones in HIV-Infected Patients: What Have We Learned? J Infect Dis 2007; 195:1731","journal-title":"J Infect Dis"},{"key":"152_CR26","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1086\/593179","volume":"198","author":"PW Mallon","year":"2008","unstructured":"Mallon, PW, Sedwell, R, Rogers, G, et al. Effect of rosiglitazone on peroxisome proliferatoractivated receptor gamma gene expression in human adipose tissue is limited by antiretroviral drug-induced mitochondrial dysfunction. J Infect Dis 2008; 198:1794.","journal-title":"J Infect Dis"},{"key":"152_CR27","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/135965350801300107","volume":"13","author":"L Slama","year":"2008","unstructured":"Slama, L, Lanoy, E, Valantin, MA, et al. Effect of pioglitazone on HIV-1-related lipodystrophy: a randomized double-blind placebo-controlled trial (ANRS 113). Antivir Ther 2008; 13:67","journal-title":"Antivir Ther"},{"key":"152_CR28","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/1471-2334-10-183","volume":"10","author":"SH Sheth","year":"2010","unstructured":"Sheth SH, Larson RJ. The efficacy and safety of insulin-sensitizing drugs in HIV-associated lipodystrophy syndrome: a meta-analysis of randomized trials. BMC Infect Dis. 2010 Jun 23;10:183.","journal-title":"BMC Infect Dis."},{"key":"152_CR29","doi-asserted-by":"crossref","unstructured":"Hansen BR, Haugaard SB, Jensen FK, et al. Long-term high-physiological-dose growth hormone reduces intra-abdominal fat in HIV-infected patients with a neutral effect on glucose metabolism. HIV Med. 2010 Apr;11(4):266-75. Epub 2009 Dec 8.","DOI":"10.1111\/j.1468-1293.2009.00775.x"},{"issue":"3","key":"152_CR30","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/QAI.0b013e3181cbdaff","volume":"53","author":"J Falutz","year":"2010","unstructured":"Falutz J, Potvin D, Mamputu JC, et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr. 2010 Mar 1;53(3):311- 22.","journal-title":"J Acquir Immune Defic Syndr."},{"issue":"3","key":"152_CR31","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1517\/13543780802707658","volume":"18","author":"Y Wang","year":"2009","unstructured":"Wang Y, Tomlinson B. Expert Tesamorelin, a human growth hormone releasing factor analogue. Opin Investig Drugs. 2009 Mar;18(3):303-10.","journal-title":"Opin Investig Drugs."},{"issue":"14","key":"152_CR32","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1097\/QAD.0b013e32830a5058","volume":"22","author":"J Falutz","year":"2008","unstructured":"Falutz J, Allas S, Mamputu JC, et al. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS. 2008 Sep 12;22(14):1719-28.","journal-title":"AIDS."},{"issue":"2","key":"152_CR33","first-page":"127","volume":"5","author":"A Lafeuillade","year":"1992","unstructured":"Lafeuillade A, Alessi MC, Poizot-Martin I, et al. Endothelial cell dysfunction in HIV infection. J Acquir Immune Defic Syndr. 1992;5(2):127-31.","journal-title":"J Acquir Immune Defic Syndr."},{"issue":"9","key":"152_CR34","first-page":"596","volume":"10","author":"S Ferraro","year":"2009","unstructured":"Ferraro S, Paolillo S, Gargiulo M, et al. Effect of antiretroviral therapy on carotid intima-media thickness in HIV-infected patients. G Ital Cardiol (Rome). 2009 Sep;10(9):596-601.","journal-title":"G Ital Cardiol (Rome)."},{"key":"152_CR35","doi-asserted-by":"crossref","unstructured":"J Acquir Immune Defic Syndr. 2009 September 1; 52(1): 25\u201331. Untreated HIV Infection and Large and Small Artery ElasticityJason V. Baker, MD, MS,*\u2020 Daniel Duprez, MD, PhD,\u2020 Joshua Rapkin, MS,\u2021 Katherine Huppler Hullsiek, PhD,\u2021 Harrison Quick, BS,\u2021 Richard Grimm, MD, PhD, James D. Neaton, PhD, and Keith Henry, MD","DOI":"10.1097\/QAI.0b013e3181b02e6a"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s11883-010-0152-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T05:56:09Z","timestamp":1712037369000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11883-010-0152-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12,23]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["152"],"URL":"https:\/\/doi.org\/10.1007\/s11883-010-0152-1","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,12,23]]}}}